Skip to content

13F-HR filed by Octagon Capital Advisors LP

Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 33 holding rows worth $624,985,827.

Accession
0001214659-24-002827
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 33 entries on the cover page, a total value of $624,985,827 stated on the cover page (in dollars after the unit check, H1), rows summing to $624,985,827 with VALUE read as dollars as filed, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
APELLIS PHARMACEUTICALS INC03753U106COM2,806,980$168,025,823dollars as filed
CYMABAY THERAPEUTICS INC23257D103COM2,673,750$63,153,975dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS2,369,000$47,095,720dollars as filed
INSMED INC COM PAR $.01457669307Stock1,284,000$39,791,160dollars as filed
ARCUS BIOSCIENCES INC03969F109COM1,868,000$35,678,800dollars as filed
BRIDGEBIO PHARMA INC10806X102COM706,800$28,533,516dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW707,526$28,060,481dollars as filed
ROIVANT SCIENCES LTDG76279101SHS2,494,000$28,007,620dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM1,241,300$23,659,178dollars as filed
STRUCTURE THERAPEUTICS INC COMP86366E106EQUITY414,000$16,874,640dollars as filed
CENTESSA PHARMACEUTICALS PLC152309100SPONSORED ADS2,060,100$16,398,396dollars as filed
AN2 THERAPEUTICS INC037326105COM664,575$13,617,142dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM620,000$13,503,600dollars as filed
IMMUNOVANT INC45258J102COM273,289$11,513,666dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock792,945$10,546,169dollars as filed
CYTOKINETICS INC23282W605COM NEW116,000$9,684,840dollars as filed
ANNEXON INC03589W102COM2,050,000$9,307,000dollars as filed
AEROVATE THERAPEUTICS INC008064107COM403,685$9,135,392dollars as filed
GOSSAMER BIO INC COM38341P102Stock9,187,883$8,383,943dollars as filed
RAPT THERAPEUTICS INC75382E109COM292,000$7,256,200dollars as filed
GLYCOMIMETICS INC38000Q102COM3,000,000$7,080,000dollars as filed
GRACELL BIOTECHNOLOGIES INC38406L103ADR596,611$5,989,974dollars as filed
DIANTHUS THERAPEUTICS INC252828108COM554,000$5,761,600dollars as filed
RENEO PHARMACEUTICALS INC75974E103COM2,250,000$3,600,000dollars as filed
JASPER THERAPEUTICS INC471871103COM4,468,114$3,525,342dollars as filed
Veru Inc92536C103Common Stock3,800,000$2,736,000dollars as filed
ANAPTYSBIO INC032724106COM120,000$2,570,400dollars as filed
INOZYME PHARMA INC45790W108COM400,000$1,704,000dollars as filed
NUVATION BIO INC COM CL A67080N101Stock1,000,000$1,510,000dollars as filed
Xilio Therapeutics Inc.98422T100COM1,785,000$981,750dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM25,000$738,000dollars as filed
PHATHOM PHARMACEUTICALS INC71722W107COMMON STOCK50,000$456,500dollars as filed
ACLARIS THERAPEUTICS INC COM00461U105Stock100,000$105,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001214659-24-002827this filing2024-02-14acceptance time not in the bulk data set